Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Authors: Dan Steven Veljovich, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Hussein Moustapha Ali-Ahmad, R. Wendel Naumann, Jean Siedel, John K. Chan, Andrew Gregory, Evan P. Pisick, Bamidele Adesunloye, Rebecca Christian Arend, Maria C Bell, Marina Frimer, Bernard Tawfik, Ramya Thota, Apostolia Maria Tsimberidou, Abby Gregory, Susan Halabi, Richard L. Schilsky

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17660

Source: Full article

---

Abstract

e17660